Drug aimed at fixing bone marrow after transplant falls short in early study
NCT ID NCT03948529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug eltrombopag in 9 people whose bone marrow did not recover well after a stem cell transplant for leukemia. The goal was to see if the drug could increase platelet counts and reduce the need for transfusions. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- A guided path back to work after blood cancer: a trial tests the impact
- Can a new tracer light up cancer growth?
- Can a different immune drug cut viral infections after stem cell transplants?
- Can simple seated exercises boost strength and Well-Being during leukemia treatment?
- Can a Child's own words improve cancer care?